Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Upstream Processing01:27

Upstream Processing

Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Armored chimeric antigen receptor T-cell therapy targets antigen-heterogeneous glioma.

Cancer research·2026
Same author

Whole-protein screening and multi-modal profiling of antigen-specific CD4<sup>+</sup> T cells at single-cell resolution.

Nature communications·2026
Same author

Engineering CAR T cells to secrete VEGF-neutralizing scFvs enhances antitumor activity against solid tumors.

Science translational medicine·2026
Same author

Human cancer-targeted immunity via transgenic hematopoietic stem cell progeny.

Nature communications·2025
Same author

IL-13Rα2/TGF-β bispecific CAR-T cells counter TGF-β-mediated immune suppression and potentiate anti-tumor responses in glioblastoma.

Neuro-oncology·2024
Same author

Extracellular domains of CARs reprogramme T cell metabolism without antigen stimulation.

Nature metabolism·2024

相关实验视频

Updated: Jun 17, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.1K

卡特-T电池制造:主要的工艺参数和下一代战略

Melanie Ayala Ceja1, Mobina Khericha1, Caitlin M Harris1

  • 1Department of Microbiology, Immunology, and Molecular Genetics, University of California-Los Angeles, Los Angeles, CA, USA.

The Journal of experimental medicine
|January 16, 2024
PubMed
概括

化学抗原受体 (CAR) -T细胞疗法是一种重要的B细胞恶性瘤治疗方法. 有效的制造是提高CAR-T细胞治疗安全性,疗效和患者可访问性的关键.

科学领域:

  • 免疫治疗是一种免疫疗法.
  • 细胞疗法细胞疗法

更多相关视频

Author Spotlight: Advancing Cell Therapy Manufacturing with Dissolvable Microcarriers
09:44

Author Spotlight: Advancing Cell Therapy Manufacturing with Dissolvable Microcarriers

Published on: July 7, 2023

3.3K
Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
06:18

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

2.6K

相关实验视频

Last Updated: Jun 17, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.1K
Author Spotlight: Advancing Cell Therapy Manufacturing with Dissolvable Microcarriers
09:44

Author Spotlight: Advancing Cell Therapy Manufacturing with Dissolvable Microcarriers

Published on: July 7, 2023

3.3K
Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
06:18

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

2.6K
  • 在瘤学瘤学.

    • 背景情况:

    • 化学抗原受体 (CAR) -T细胞疗法在治疗B细胞恶性瘤方面取得了重大进展,具有强大的治愈潜力.
    • 卡特-T细胞疗法的成功应用范围超越了血液癌症,扩展到固体瘤和自身免疫性疾病.
    • 有效的制造工艺对于这些先进疗法的安全性,有效性和广泛可用性至关重要.

    结论:

    • 优化CAR-T细胞制造对于实现这种方法的全部治疗潜力至关重要.
    • 应对制造业的挑战将提高更广泛的患者群体的治疗可用性.
    • 在CAR-T细胞制造领域的持续研究和开发对于未来的治疗突破至关重要.